Temporomandibular joint osteoarthritis (TMJOA) is an important subtype of temporomandibular disorders characterized by progressive cartilage degradation, subchondral bone remodeling, synovial inflammation, chronic pain, and joint crepitus, adversely affecting the quality of life.1 Current management with non-steroidal anti-inflammatory drugs, intra-articular hyaluronic acid injections, or arthrocentesis reduces pain and inflammation to some extent, but does not repair the joint, underscoring the need for effective disease-modifying therapies.1